Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Obesity is associated with several cardiometabolic complications, which reduce the quality of life as well as life expectancy
Contact your healthcare provider for advice
Novo Nordisk later capitalized on these weight loss effects by releasing Wegovy in June 2021, which contains higher doses of the same semaglutide molecule but carries FDA approval specifically for chronic weight management
Smith, BS, PharmD Candidate 2021 College of Pharmacy and Pharmaceutical Sciences Washington State University Joshua J
Heres a look at some recent weight loss results for semaglutide : In a phase 3 clinical trial of people with obesity, people taking the Wegovy injection (2.4 mg injectable semaglutide) lost an average of 14.9% of their body weight in 68 weeks (about a year and four months)
US$ 29.14
US$ 28.79
US$ 20.81
